Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Expanding US operations to address the increased demand for API development and manufacturing
This new facility strengthens Latin America as a collaborative hub
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Subscribe To Our Newsletter & Stay Updated
